Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial

被引：2
|
作者：
Harbeck, N. [1 ]
Vazquez, R. Villanueva [2 ]
Tripathy, D. [3 ]
Lu, Y. [4 ]
De Laurentiis, M. [5 ]
Kuemmel, S. [6 ]
Taylor, D. [7 ]
Bardia, A. [8 ]
Hurvitz, S. [9 ]
Chow, L. [10 ]
Im, S. [11 ]
Franke, F. [12 ]
Hughes, G. [13 ]
Miller, M. [13 ]
Kong, O. [13 ]
Chandiwana, D. [13 ]
Colleoni, M. [14 ]
机构：
[1] Univ Munich LMU, Dept OB & GYN, Breast Ctr, Munich, Germany
[2] Hosp St Joan Despi Moises Broggi, Inst Catala Oncol, Barcelona, Spain
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Ist Nazl Tumori Fdn G Pascale, Naples, Italy
[6] Kliniken Essen Mitte, Breast Unit, Essen, Germany
[7] CHU UCL Namur Site St Elisabeth, Namur, Belgium
[8] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[9] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[10] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China
[11] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea
[12] Hosp Caridade Ijui, CACON, Ijui, Brazil
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Ist Europeo Oncol, Div Med Senol, Milan, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
10.1016/S0959-8049(18)30260-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1LBA
引用
收藏
页码：S3 / S3
页数：1
相关论文
共 50 条
  • [41] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
    Slamon, Dennis J.
    Fasching, Peter A.
    Patel, Ravindranath
    Verma, Sunil
    Hurvitz, Sara A.
    Chia, Stephen K. L.
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Spera, Gonzalo
    Lopez, Celine
    Hor, Ines
    Pelov, Diana
    Hughes, Gareth
    Nawinne, Moditha
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [43] Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
    Tripathy, Debu
    Im, Seock-Ah
    Colleoni, Marco
    Franke, Fabio
    Bardia, Aditya
    Harbeck, Nadia
    Hurvitz, Sara A.
    Chow, Louis
    Sohn, Joohyuk
    Lee, Keun Seok
    Campos-Gomez, Saul
    Vazquez, Rafael Villanueva
    Jung, Kyung Hae
    Babu, K. Govind
    Wheatley-Price, Paul
    De laurentiis, Michelino
    Im, Young-Hyuck
    Kuemmel, Sherko
    El-Saghir, Nagi
    Liu, Mei-Ching
    Carlson, Gary
    Hughes, Gareth
    Diaz-Padilla, Ivan
    Germa, Caroline
    Hirawat, Samit
    Lu, Yen-Shen
    LANCET ONCOLOGY, 2018, 19 (07): : 904 - 915
  • [44] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
    Engel-Nitz, Nicole M.
    Hao, Yanni
    Rogerio, Jaqueline Willemann
    Turnbull, James D.
    Rey, Gabriel Gomez
    Sullivan, Jane
    Rossof, Arthur H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [45] Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review
    Carter, Gebra Cuyun
    Mohanty, Maitreyee
    Stenger, Keri
    Guimaraes, Claudia Morato
    Singuru, Shivaprasad
    Basa, Pradeep
    Singh, Sheena
    Tongbram, Vanita
    Kuemmel, Sherko
    Guarneri, Valentina
    Tolaney, Sara M.
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 6537 - 6566
  • [46] Ribociclib (RIBO) plus letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
    Abdel-Razeq, H.
    Cottu, P. H.
    Ring, A.
    De laurentiis, M.
    Lu, J.
    Azim, H. A.
    Zamagni, C.
    Zhou, K.
    Wu, J.
    Menon, L.
    Martin, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] HORMONE RECEPTOR-POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER (ABC): TESTING PATTERNS, PRESCRIBING BEHAVIOR, AND TREATMENT OPTION PERCEPTIONS AMONG US ONCOLOGISTS
    Miller, T.
    Savill, K.
    Jeune-Smith, Y.
    Leon, B.
    Brown, M.
    Klink, A.
    Feinberg, B.
    VALUE IN HEALTH, 2022, 25 (12) : S277 - S277
  • [48] Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib
    Tripathy, Debu
    Im, Seock-Ah
    Colleoni, Marco
    Franke, Fabio
    Bardia, Aditya
    Harbeck, Nadia
    Hurvitz, Sara
    Chow, Louis
    Sohn, Joohyuk
    Lee, Keun Seok
    Campos-Gomez, Saul
    Vazquez, Rafael Villanueva
    Jung, Kyung Hae
    Babu, K. Govind
    Wheatley-Price, Paul
    De laurentiis, Michelino
    Im, Young-Hyuck
    Kummel, Sherko
    El-Saghir, Nagi
    Liu, Mei-Ching
    Kaur, Sharonjeet
    Gasch, Claudia
    Wang, Craig
    Wang, Yongyu
    Chakravartty, Arunava
    Lu, Yen-Shen
    Liu, Mei-Ching
    CANCER RESEARCH, 2021, 81 (04)
  • [49] RIBOCICLIB (RIB) plus LETROZOLE (LET) IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL RECEPTOR-2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) BY DOSE INTENSITY: PRELIMINARY SUBGROUP RESULTS FROM THE PHASE 3B COMPLEEMENT-1 TRIAL
    Farhat, Fadi
    Martin, Miguel
    Campone, Mario
    Bachelot, Thomas
    Neven, Patrick
    Martinez Rodriguez, Jorge Luis
    Yusof, Mastura Md
    Papazisis, Konstantinos
    Ferreira, Ana
    Ankrah, Nii
    Wu, Jiwen
    Zhou, Katie
    De laurentiis, Michelino
    BREAST, 2019, 48 : S46 - S46
  • [50] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
    Mistry, R.
    Suri, G.
    Young, K. C.
    Hettle, R.
    May, J. R.
    Brixner, D.
    Oderda, G.
    Biskupiak, J.
    Tang, D.
    Bhattacharyya, D.
    Bhattacharyya, S.
    Mishra, D.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A422 - A423
12345